CHIKUNGUNYA VIRUS INFECTION
Clinical trials for CHIKUNGUNYA VIRUS INFECTION explained in plain language.
Never miss a new study
Get alerted when new CHIKUNGUNYA VIRUS INFECTION trials appear
Sign up with your email to follow new studies for CHIKUNGUNYA VIRUS INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chikungunya vaccine enters first human safety trial
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage trial tests a new vaccine called PepGNP-ChikV, made from tiny synthetic particles, to see if it is safe and triggers an immune response against chikungunya virus. Forty healthy adults aged 18 to 60 will receive two doses 42 days apart. The study focuses on safety…
Matched conditions: CHIKUNGUNYA VIRUS INFECTION
Phase: EARLY_PHASE1 • Sponsor: Gylden Pharma Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:24 UTC
-
Chikungunya vaccine safety checked in pregnant women
Knowledge-focused Not yet recruitingThis study follows 200 pregnant women in Brazil who received the chikungunya vaccine (VLA1553) during pregnancy or shortly before. Researchers will track pregnancy and infant health up to 12 weeks after birth, comparing them to a similar group of women who got routine vaccines. T…
Matched conditions: CHIKUNGUNYA VIRUS INFECTION
Sponsor: Valneva Austria GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC